2023
Obesity and Overweight: Probing Causes, Consequences, and Novel Therapeutic Approaches Through the American Heart Association's Strategically Focused Research Network
Clark J, Garvey W, Niswender K, Schmidt A, Ahima R, Aleman J, Battarbee A, Beckman J, Bennett W, Brown N, Chandler‐Laney P, Cox N, Goldberg I, Habegger K, Harper L, Hasty A, Hidalgo B, Kim S, Locher J, Luther J, Maruthur N, Miller E, Sevick M, Wells Q. Obesity and Overweight: Probing Causes, Consequences, and Novel Therapeutic Approaches Through the American Heart Association's Strategically Focused Research Network. Journal Of The American Heart Association 2023, 12: e027693. PMID: 36752232, PMCID: PMC10111504, DOI: 10.1161/jaha.122.027693.Peer-Reviewed Original ResearchConceptsAmerican Heart AssociationHeart AssociationWeight loss interventionNovel therapeutic approachesVanderbilt University Medical CenterUniversity Medical CenterEffective therapeutic interventionsField of obesityResearch NetworkLoss interventionClinical trialsWorldwide prevalenceMedical CenterTherapeutic approachesObesityTherapeutic targetAnimal modelsJohns Hopkins University SchoolTherapeutic interventionsIndividual centersNew targetsUniversity of AlabamaOverweightUniversity SchoolIntervention
2017
Pharmacogenomics of off‐target adverse drug reactions
Garon SL, Pavlos RK, White KD, Brown NJ, Stone CA, Phillips EJ. Pharmacogenomics of off‐target adverse drug reactions. British Journal Of Clinical Pharmacology 2017, 83: 1896-1911. PMID: 28345177, PMCID: PMC5555876, DOI: 10.1111/bcp.13294.Peer-Reviewed Original ResearchConceptsAdverse drug reactionsSevere cutaneous adverse reactionsTarget adverse drug reactionsDrug reactionsImmunological memoryTherapeutic effectHuman leukocyte antigen (HLA) associationsCutaneous adverse reactionsStrong human leukocyte antigen (HLA) associationDrug therapeutic effectsIM-ADRsMaculopapular exanthemaClinical featuresOptimal therapySignificant morbidityAdverse reactionsAntigen associationsPharmacological actionsTherapeutic targetDisease pathophysiologyClinical phenotypePreclinical testingGreater riskDrug metabolismPatient safety